TScan Therapeutics

TCRX · NASDAQ

$0.224+$0.0138 (+6.57%)TodayMarket closed · Oct 20, 7:39 PM ET

Prev close $0.2102

Latest news

NewsOct 20, 5:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsSep 2, 12:01 PM ETAvi Kapoor
Crude Oil Moves Higher; US Factory Orders Rise In July
NewsSep 2, 11:36 AM ETVandana Singh
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction
NewsSep 2, 9:42 AM ETAvi Kapoor
Dow Surges Over 200 Points; Ollie's Bargain Outlet Shares Gain After Q2 Earnings
Press releaseSep 2, 7:00 AM ETGlobe Newswire
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
NewsAug 19, 5:05 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseAug 12, 7:00 AM ETGlobe Newswire
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Press releaseJul 29, 7:00 AM ETGlobe Newswire
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
Press releaseJun 22, 7:00 AM ETGlobe Newswire
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
Press releaseJun 3, 9:19 AM ETBusiness Wire
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
Press releaseMay 6, 7:00 AM ETGlobe Newswire
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
NewsApr 21, 5:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseMar 19, 10:00 AM ETPRNewswire
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
NewsMar 13, 8:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsMar 4, 7:12 AM ET
Earnings Breakdown: TScan Therapeutics Q4
Press releaseMar 4, 7:00 AM ETGlobe Newswire
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Press releaseFeb 26, 7:00 AM ETGlobe Newswire
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
NewsFeb 13, 4:06 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
Press releaseDec 19, 7:55 AM ETPRNewswire
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Press releaseDec 4, 12:20 PM ETPRNewswire
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Press releaseNov 12, 7:00 AM ETGlobe Newswire
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
NewsNov 3, 12:05 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsNov 3, 7:05 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
Press releaseNov 3, 6:30 AM ETGlobe Newswire
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
Press releaseMay 23, 9:10 AM ETPRNewswire
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs
NewsMay 7, 9:00 AM ET
What Analysts Are Saying About TScan Therapeutics Stock
Press releaseMay 6, 7:00 AM ETGlobe Newswire
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
NewsApr 8, 9:00 AM ET
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts
NewsMar 6, 7:00 AM ET
Breaking Down TScan Therapeutics: 4 Analysts Share Their Views
NewsDec 26, 7:16 AM ET
Market-Moving News for December 26th
NewsDec 11, 9:01 AM ET
The Analyst Landscape: 5 Takes On TScan Therapeutics
Press releaseDec 5, 8:00 AM ETGlobe Newswire
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
Press releaseNov 12, 7:00 AM ETGlobe Newswire
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
NewsNov 6, 7:00 AM ET
Demystifying TScan Therapeutics: Insights From 4 Analyst Reviews
NewsAug 13, 10:00 AM ET
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts
Press releaseAug 12, 7:00 AM ETGlobe Newswire
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

12 Health Care Stocks Moving In Tuesday's After-Market Session

Crude Oil Moves Higher; US Factory Orders Rise In July

TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction

Dow Surges Over 200 Points; Ollie's Bargain Outlet Shares Gain After Q2 Earnings

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

12 Health Care Stocks Moving In Wednesday's After-Market Session

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

Earnings Scheduled For May 6, 2026

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

12 Health Care Stocks Moving In Tuesday's After-Market Session

Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care

12 Health Care Stocks Moving In Friday's Pre-Market Session

Earnings Breakdown: TScan Therapeutics Q4

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

12 Health Care Stocks Moving In Friday's After-Market Session

Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Pre-Market Session

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs

What Analysts Are Saying About TScan Therapeutics Stock

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts

Breaking Down TScan Therapeutics: 4 Analysts Share Their Views

Market-Moving News for December 26th

The Analyst Landscape: 5 Takes On TScan Therapeutics

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Demystifying TScan Therapeutics: Insights From 4 Analyst Reviews

Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update